NCT06584656Completed
Understanding Cerebral Blood Flow Dynamics for Alzheimer's Disease Prevention Through Exercise
Understanding Cerebral Blood Flow Dynamics for Alzheimer's Disease Prevention Through Exercise: the flADex Study
Source: ClinicalTrials.gov · Last updated 25 Mar 2025
Brief summary (registry, in English)
Dementia is one of the leading causes of disability worldwide. Underlying biological mechanisms are crucial in preclinical stages of Alzheimer's disease (AD). Alterations in cerebral blood flow (CBF) and their relationship with AD blood-based biomarkers may be fundamental at early stages of the pathology. Physical exercise is a trigger to modify these biological mechanisms. Therefore, flADex aims to examine the acute effects of different types of exercise (resistance vs. aerobic vs. control) on CBF, AD blood-based biomarkers, and its cognitive implications in older adults. The hypothesis is that acute resistance or aerobic exercise will fluctuate levels of blood-based biomarkers, and will exert acute CBF changes combined with cognitive implications.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 20 (actual)
- First submitted
- 6 Aug 2024
- Start date
- 25 Sept 2024
- Primary completion date
- 2 Jan 2025
- Lead sponsor
- Universidad de Granada
- Diseases
- Alzheimer disease
- NCT number
- NCT06584656
What you commit to
- Study type: Interventional
- Participants enrolled: 20
- From 25 Sept 2024 to the primary completion date, 2 Jan 2025
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Pathological diagnosis related to physical or mental condition
- Severe cardiovascular or respiratory conditions
Other
- No living in community settings during the study
- MRI incompatibility
- Ambulatory with pain or regular use of an assisted walking device
- Participation in another clinical trial within the last 30 days
Who the study is looking for
- Older adults
- Aged 68-83 years
- Non-pathological cerebral beta-amyloid status (based on Centiloid cut-point \<12 measured by PET-CT)
- APOEe4 negative status
- Willingness to participate in exercise interventions
Age in the registry: 68 years to 83 years · Sex: All · Accepts healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Mind, Brain, and Behaviour Research Centre (CIMCYC, Centro de Investigación Mente, Cerebro y Comportamiento) Coordinator of this site? Confirm its status | Granada | Spain | Unknown status |
| University of Granada Coordinator of this site? Confirm its status | Granada | Spain | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.